Anti-Xa bioassays for the laboratory measurement of direct Factor Xa inhibitors in plasma, in selected patients

摘要: In the past decade Direct Oral Anti-Coagulants (DOACs), targeting Thrombin or Factor Xa, have enormously facilitated daily treatment of all relevant patients, including those requiring lifelong therapy. These DOACs considerable advantages over use oral Vitamin K Antagonist (VKA) treatments, in view having little interferences with food and other medications also not adjustment for age, gender weight, some well-defined exceptions. this current What's Happening Section we focus on measurements DiXaIs plasma using anti-Xa assays, objective providing a tribute to Professor Michel Meyer Samama, who was only real leader field but, past, both authors benefited from his wisdom, as teacher dedicated scientific professional life (among many interests hemostasis, thrombosis fibrinolysis) develop promote methods strategies laboratory monitoring anticoagulants. This review presents performance characteristics Anti-Factor Xa assays (measuring inhibition by drugs), which are available measuring Inhibitors plasma, show good compliance results reference LC:MS method (which measures mass Inhibitors). We present preparation validation drug specific calibrators controls requested measurements. convenient practical tools can be used any setting, meet requirements regulatory bodies making smart, quantitative, sensitive, accurate ease when needed. The manuscript focuses mainly following areas interest: interference coagulation assays; methods; development DiXaIs; comparison techniques (LC:MS); registrations; newer clinical applications experience Anti-Xa future perspectives.